Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,313,054
  • Shares Outstanding, K 96,478
  • Annual Sales, $ 560,230 K
  • Annual Income, $ -569,180 K
  • EBIT $ -544 M
  • EBITDA $ -521 M
  • 60-Month Beta 0.16
  • Price/Sales 6.24
  • Price/Cash Flow N/A
  • Price/Book 381.63

Options Overview Details

View History
  • Implied Volatility 158.23% (-4.56%)
  • Historical Volatility 47.83%
  • IV Percentile 99%
  • IV Rank 93.35%
  • IV High 166.83% on 12/12/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 2) 1.79 (5.20%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 1,508
  • Volume Avg (30-Day) 2,146
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 72,829
  • Open Int (30-Day) 67,566
  • Expected Range 32.56 to 36.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.32
  • Number of Estimates 10
  • High Estimate -0.96
  • Low Estimate -1.87
  • Prior Year -1.39
  • Growth Rate Est. (year over year) +5.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.00 +10.77%
on 11/20/25
39.89 -13.91%
on 12/08/25
+1.26 (+3.81%)
since 11/14/25
3-Month
27.75 +23.75%
on 09/25/25
39.89 -13.91%
on 12/08/25
+4.86 (+16.49%)
since 09/16/25
52-Week
25.81 +33.05%
on 07/21/25
46.50 -26.15%
on 02/06/25
-11.06 (-24.36%)
since 12/16/24

Most Recent Stories

More News
Ultragenyx to Participate in Investor Conferences in December

NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 34.34 (-5.22%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 34.34 (-5.22%)
Ultragenyx: Q3 Earnings Snapshot

Ultragenyx: Q3 Earnings Snapshot

RARE : 34.34 (-5.22%)
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update

Third quarter total revenue of $160 million,  Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670...

RARE : 34.34 (-5.22%)
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55...

RARE : 34.34 (-5.22%)
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups

NOVATO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the  Aurora study (NCT07157254) evaluating the...

RARE : 34.34 (-5.22%)
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

RARE : 34.34 (-5.22%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 34.34 (-5.22%)
Bank of America Securities Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $79.00. The company’s shares closed yesterday at $30.90.Elevate Your...

RARE : 34.34 (-5.22%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 34.34 (-5.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 38.21
2nd Resistance Point 37.37
1st Resistance Point 35.86
Last Price 34.34
1st Support Level 33.51
2nd Support Level 32.67
3rd Support Level 31.15

See More

52-Week High 46.50
Fibonacci 61.8% 38.60
Fibonacci 50% 36.15
Last Price 34.34
Fibonacci 38.2% 33.71
52-Week Low 25.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar